Mobile applications and improving the quality of life in people with obesity

Mustač, Filip; Tomasic, Lea; Peček, Mirta; Galijasevic, Tin; Grkinic, Andrea; Medic, Filip; Matovinović, Martina; Marčinko, Darko

doi:10.23919/splitech55088.2022.9854214

Cited by 1 publication

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the very use of any drug that is related to weight loss calls into question one's own active role in terms of whether something happens because of that medication or because of one's own behavior, which calls into question one's own motivation and requires a certain level of adaptation to the situation itself and direction of behavior. Mobile applications that can be used to quickly and easily monitor caloric intake and body wight and encourage exercise certainly play an interesting role [31,32]. Awareness of the problem of obesity can certainly be one of the focuses and therapeutic goals in psychotherapy, and an integrative approach that, together with an endocrinologist who deals specifically with obesity, together with a psychologist and a psychiatrist, can certainly help more than without psychological support [30,33].…”

Section: Discussionmentioning

confidence: 99%

Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?

Matovinović,

Belančić,

Jug

et al. 2024

Diabetology

View full text Add to dashboard Cite

Background: Diabetes is the primary contributor to cardiovascular disease risk, and when combined with obesity, it further underscores the significance of cardiovascular risk assessment. Methods: A retrospective study of 64 patients with type 2 diabetes (T2D) and obesity on once-weekly subcutaneous semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes, and ASCVD score calculations. We compare the differences between groups (ASCVD: low + borderline + intermediate versus high-risk group; SCORE2/SCORE2-OP: low + moderate versus high + very high-risk group and SCORE2-Diabetes: low + moderate versus high + very high-risk group) in terms of change from baseline in body mass index (BMI) and HbA1c and weight loss outcomes. Results: Patients in the high-risk group, according to ASCVD risk score, had statistically better results in weight loss ≥ 3%, ≥5%, and ≥10% compared to ASCVD low + borderline + intermediate and without difference regarding HbA1c. According to SCORE2/SCORE2-OP, the high + very high-risk group had statistically better HbA1c and weight loss results but only for ≥5% versus the low + moderate risk group. Based on the score SCORE2-Diabetes, the high + very high-risk group had statistically significant better results in lowering HbA1c and weight loss but only for ≥5% versus the low + moderate risk group. Conclusions: To the best of our knowledge, this study represents the initial investigation linking glycemic control and weight reduction outcomes in individuals with T2D and obesity treated with once-weekly semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes and ASCVD score calculations.

show abstract

Section: Discussionmentioning

confidence: 99%